Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Income from Continuing Operations (2022 - 2025)

Axsome Therapeutics' Income from Continuing Operations history spans 4 years, with the latest figure at 28629000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 61.78% year-over-year to 28629000.0; the TTM value through Dec 2025 reached 183204000.0, up 36.21%, while the annual FY2025 figure was 183204000.0, 36.21% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 28629000.0 at Axsome Therapeutics, up from 47189000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 11238000.0 in Q1 2023 and bottomed at 98673000.0 in Q4 2023.
  • The 4-year median for Income from Continuing Operations is 60327000.0 (2022), against an average of 56049500.0.
  • The largest annual shift saw Income from Continuing Operations soared 71.64% in 2023 before it plummeted 508.27% in 2024.
  • A 4-year view of Income from Continuing Operations shows it stood at 61241000.0 in 2022, then crashed by 61.12% to 98673000.0 in 2023, then grew by 24.08% to 74912000.0 in 2024, then skyrocketed by 61.78% to 28629000.0 in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Income from Continuing Operations are 28629000.0 (Q4 2025), 47189000.0 (Q3 2025), and 47973000.0 (Q2 2025).